Scouting report · NKTR

Howard W. Robin

Nektar's President & CEO since January 2007; earlier Sirna CEO and Berlex CFO

Born / age
(73)
Role
President & CEO; director
In the role
20 yr
Education
BS Fairleigh Dickinson University
Front Office rank
not ranked yet
NKTR
Nektar TherapeuticsBiotech binary
Title
President & CEO; directorsrc
In role
since 2007-01 (20 yr)
Stake value—no holding or price on file
—thin record

Scouting sheetas of 25 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design40strategic, time only · 99.1% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
99%Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
Howard W. Robin
Age
73src
Education
BS Accounting and Finance, Fairleigh Dickinson Universitysrc

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
429,483 NKTR, 2026-04-06src
Share of company
1.4%
Traded, 12 months
bought $0, sold $1.2msrc
Last pay
$6.3m 2025src
Say-on-pay vote
99.1% forsrc

What to weigh

Red flag 1

  • Pay-versus-performance table: $100 invested at end-2020 was worth $16.58 at end-2025 against $124.75 for the peer index; GAAP net loss $164m in 2025 and every year shownsrc

Watch 5

  • Re-elected in June 2026 with about 72.6% of votes cast for (13.16m for, 4.98m against), a weak result for a sole nomineesrc
  • Change-of-control plan (2006) gives him 24 months of salary plus target bonus, full equity acceleration and a grandfathered excise-tax gross-upsrc
  • Bonus pays on a board-scored corporate rating (75% rezpegaldesleukin milestones). 2025 raw score was 90-96%; the board lifted it to 100% for goals not set at the start of the year, with the financial goal scored zerosrc
  • Sold 20,000 shares on 2026-06-16/17 (about $1.2m) under a 10b5-1 plan adopted 2026-03-13src
  • Also sold about 20,000 shares on 2025-09-02/04/05/09 under an earlier 10b5-1 plan, as the stock ran from about $30 to $48 after the Phase 2b datasrc

In their favour 2

  • The relative-TSR RSUs granted in 2020 and 2021 paid nothing and were cancelled, as were the bempegaldesleukin performance grants after that programme failedsrc
  • Hedging and pledging banned; 3x-salary ownership guideline met or within grace period at 2025 year endsrc

Pay

Salary and otherBonus, stock, options, incentive

  • $3.1m2023
  • $3.8m2024
  • $6.3m2025
The table
YearSalaryBonusStockOptionsIncentiveOtherTotal
2023$1.1m$0$0$927k$1.0m$93k$3.1msrc
2024$1.1m$0$0$1.6m$976k$106k$3.8msrc
2025$1.1m$0$942k$3.0m$1.1m$116k$6.3msrc
Bonus pays on
Cash bonus target 100% of salary, paid solely on the board's corporate performance rating (2025: rezpegaldesleukin 75%, NKTR-0165/0166 10%, financial/BD 15%); paid at 100%
Long-term award pays on
December 2025 grant: 86,667 time-based options and 21,667 time-based RSUs (four-year vesting) plus 21,667 performance RSUs that vest only on full enrollment of both Phase 3 atopic dermatitis monotherapy studies within four yearssrc
  • Pay at risk not on file
  • Pays on returns strategic, time only
  • Shareholder vote 99.1% for
  • Pay vs profit company lost money

Career

  1. 2007 – now
    Nektar Therapeuticssrc
    President & CEO; director since February 2007
    Took over in January 2007; has run the company through the bempegaldesleukin (oncology) programme's 2022 failure and the pivot to immunology (rezpegaldesleukin)
  2. 2001 – 2006
    Sirna Therapeuticssrc
    President & CEO and director (Jul 2001-Nov 2006); COO, President and director (Jan-Jun 2001)
    RNAi company later acquired by Merck (DEF14A-2026)
  3. 1991 – 2001
    Berlex Laboratories (U.S. subsidiary of Schering AG)src
    Corporate Vice President and General Manager, therapeutics division
    Responsible for Betaseron and Fludara per DEF14A-2026
  4. 1987 – 1991
    Berlex Laboratoriessrc
    Vice President of Finance and Business Development and CFO
  5. 1984 – 1987
    Berlex Laboratoriessrc
    Director of Business Planning and Development

Undated in the sources

  • Arthur Andersen & Co.src, Senior Associate

Not located: Arthur Andersen years not stated; December 2006 between Sirna and Nektar not described

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Family The 2026 proxy counts 28 shares held by his spouse in his beneficial ownership. Neither the 2026 proxy nor the FY2025 10-K carries an Item 401(d) family-relationship statementsrc
  • Boards Former member of the Fairleigh Dickinson University Board of Trustees (the 2021 proxy said he was serving; the 2026 proxy says previously)src
  • Boards Former outside boards per the search summary: Inogen (2015-2021), Sientra (2014-2018), Versartis (2014-2018), Auspex Pharmaceuticals (2014-2015), StemCells Inc. (2010-2016) and Ablexis as chairman (2010-2016). No current outside public board in the 2026 proxy biosrc
  • Legal Named defendant, with Nektar and two scientists, in a securities class action over 2017-2018 statements on bempegaldesleukin trial data; dismissed, and the Ninth Circuit affirmed the dismissal on 2022-05-19src
  • Other Recommends the other executives' pay and gives the board input on the corporate performance rating that sets his own bonus; he does not take part in deciding his own paysrc

Sources11